Svensson L A
Research and Development Department, AB DRACO, Lund, Sweden.
Agents Actions Suppl. 1988;23:271-6. doi: 10.1007/978-3-0348-9156-1_20.
As exemplified with bambuterol, a bronchodilator prodrug with sustained action, increased therapeutic selectivity can be obtained as a result of altered tissue distribution and pharmacokinetics rather than of increased beta 2-adrenoceptor selectivity.